“Cognitive enhancement drugs only have short-term benefits and can cause significant side-effects for people with mild memory problems, according to researchers. In a new review of existing data, researchers at St. Michael’s Hospital in Toronto, Canada studied eight randomized clinical trials and three companion reports on the efficacy of four drugs in people with mild cognitive impairment. The drugs were donepezil (Aricept), rivastigmine (Exelon), galantamine (Razadyne), and memantine (Namenda). They found that while the drugs do have short-term benefits, they are lost after a year and a half of treatment.”
1Kn9WEFymnCiU9W6AwvQej27cW5hKsYZuU
